Last updated: 2026-11-15 12:45:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tempest Therapeutics, Inc. (TPST) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.38, with a market capitalization of $7.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.34 to $9.75. This page covers its latest market performance, valuation, price trends and company information.
$7.64M | |
$0.38 | |
$0.42 | |
$0.37 | |
$0.38 | |
150.08K | |
2.60M | |
-- | |
$9.75 | |
$0.34 | |
-- | |
-- |
Tempest Therapeutics, Inc. (TPST) last closed at $0.38 as of 2026-11-14 00:58:00, down 0.26% ($0.00) from the previous close of $0.38.
During the latest regular trading session, TPST traded between $0.37 and $0.42, with a volume of 150.08K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Tempest Therapeutics, Inc. (TPST) moved from $0.38 to $0.38, representing a gain of 1.81% ($0.01).
The stock traded between $0.34 and $0.48 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 386.12 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.5%
TPST is currently trading at $0.38, placing it 0.5% of the way from its 52-week low of $0.34 to its 52-week high of $9.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Tempest Therapeutics, Inc. and TPST stock.
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.32) by 34.38 percent. This is a 73.42 percent increase over losses of $(0.79) per share
Tempest Therapeutics (TPST) announced it has exercised an option to obtain exclusive global rights (excluding China) to Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T candidates. The company's lead candidate TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T, is in Phase 1 trials for relapsed/refractory multiple myeloma with encouraging preliminary results expected to be presented at an upcoming conference. Tempest also secured $50 million in equity line of credit access and $2.5 million in private placement funding, while strengthening its board with two new independent directors.
Eligible investors can buy real shares of Tempest Therapeutics, Inc. (TPST) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TPST, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TPST shares and USD.
TPST Shares to USD
1.00 TPST shares = 0.382 USD
Calculations are estimates based on the latest available price and are for reference only.
